» Articles » PMID: 39213052

Identification of a Novel Necroptosis-related LncRNA Signature for Prognostic Prediction and Immune Response in Oral Squamous Cell Carcinoma

Overview
Journal Cancer Biomark
Publisher Sage Publications
Specialties Biochemistry
Oncology
Date 2024 Aug 30
PMID 39213052
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Necroptosis is a caspase-independent regulated necrotic cell death modality that elicits strong adaptive immune responses, and has the potential to activate antitumor immunity. Long non-coding RNAs (lncRNAs) have critical effects on oral squamous cell carcinoma (OSCC), which are closely associated with the prognosis and immune regulation of OSCC patients.

Objective: This study aimed to identify a novel necroptosis-related lncRNAs signature to predict the prognosis and immune response of OSCC patients and provide patients with anti-tumor drug selection through bioinformatics analysis and in vitro experiments.

Methods: A series of analyses, including differential lncRNA screening, survival analysis, Cox regression analysis, ROC analysis, nomogram prediction, enrichment analysis, tumor-infiltrating immune cells, drug sensitivity analysis, and consensus cluster analysis, were performed to determine and validate the prognostic value of necroptosis-associated lncRNAs signature in OSCC. And real-time quantitative polymerase chain reaction (RT-qPCR) was used to determine the expression levels of these lncRNAs.

Results: This signature including 5 lncRNAs (AC099850.3, StarD4-AS1, AC011978.1, LINC01503, CDKN2A-DT) in OSCC associated with necroptosis were established and verified by bioinformatics. Further, ROC, K-M, univariate/multivariate Cox regression, and nomogram analysis were used to evaluate the model's features for OSCC prognosis. Using multiple bioinformatics techniques, the levels of tumor-infiltrating immune cells, immune checkpoints and semi-inhibitory concentrations showed significant differences across risk subtypes. By consensus cluster analysis, there were significant differences between clusters in survival, immune checkpoint expression, clinicopathological correlation, and tumor immunity. RT-qPCR showed that AC099850.3, AC011978.1, LINC01503 were up-regulated, STARD4-AS1 and CDKN2A-DT were down-regulated in OSCC cell lines compared with human normal oral keratinoid cell line.

Conclusion: We established 5-NRLs markers, which is useful for assessing OSCC immune response and prognosis, recommending personalized antitumor drugs. The expression level of 5-NRLs in OSCC was identified in vitro, and the results preliminarily verified this model. And this study would generate new insights for future experimental research.

Citing Articles

Tumor-Educated Platelets lncRNA-STARD4-AS1 and ELOA-AS1 as Potential Novel Biomarkers for the Early Diagnosis of Non-Small Cell Lung Cancer.

Luo C, Lin Z, Huang F, Ning L, Yuan Y Cancer Manag Res. 2025; 17():1-9.

PMID: 39781562 PMC: 11705986. DOI: 10.2147/CMAR.S498516.

References
1.
Yang Y, Chen D, Liu H, Yang K . Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma. Cell Death Dis. 2019; 10(2):41. PMC: 6381212. DOI: 10.1038/s41419-018-1280-8. View

2.
Chen H, Xie Z, Li Q, Qu G, Tan N, Zhang Y . Risk coefficient model of necroptosis-related lncRNA in predicting the prognosis of patients with lung adenocarcinoma. Sci Rep. 2022; 12(1):11005. PMC: 9243036. DOI: 10.1038/s41598-022-15189-4. View

3.
Peltier D, Roberts A, Reddy P . LNCing RNA to immunity. Trends Immunol. 2022; 43(6):478-495. PMC: 9647660. DOI: 10.1016/j.it.2022.04.002. View

4.
Shen Y, Peng X, Shen C . Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics. 2020; 112(3):2640-2646. DOI: 10.1016/j.ygeno.2020.02.015. View

5.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View